Basilea Pharmaceutica AG
SIX:BSLN
Basilea Pharmaceutica AG
Inventory
Basilea Pharmaceutica AG
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Inventory
CHf21.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
8%
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Inventory
$18m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Inventory
CHf86m
|
CAGR 3-Years
66%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Inventory
CHf11.9m
|
CAGR 3-Years
72%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Inventory
CHf923k
|
CAGR 3-Years
56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
See Also
What is Basilea Pharmaceutica AG's Inventory?
Inventory
21.6m
CHF
Based on the financial report for Dec 31, 2025, Basilea Pharmaceutica AG's Inventory amounts to 21.6m CHF.
What is Basilea Pharmaceutica AG's Inventory growth rate?
Inventory CAGR 10Y
8%
Over the last year, the Inventory growth was -32%. The average annual Inventory growth rates for Basilea Pharmaceutica AG have been -4% over the past three years , and 8% over the past ten years .
